Cargando…
Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD
Trimethylamine-N-oxide (TMAO) is a molecular metabolite derived from the gut flora, which has recently emerged as a candidate risk factor for metabolic dysfunction-associated fatty liver disease (MAFLD). TMAO is mainly derived from gut, where the gut microbiota converts TMA precursors into TMA, whic...
Autores principales: | Li, Xun, Hong, Jia, Wang, Yao, Pei, Maohua, Wang, Luwen, Gong, Zuojiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517136/ https://www.ncbi.nlm.nih.gov/pubmed/34660695 http://dx.doi.org/10.3389/fmolb.2021.733507 |
Ejemplares similares
-
Implications of trimethylamine N-oxide (TMAO) and Betaine in Human Health: Beyond Being Osmoprotective Compounds
por: Ilyas, Ashal, et al.
Publicado: (2022) -
Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure
por: Wang, Yao, et al.
Publicado: (2021) -
Simultaneous Measurement of Urinary Trimethylamine (TMA) and Trimethylamine N-Oxide (TMAO) by Liquid Chromatography–Mass Spectrometry
por: Jia, Xun, et al.
Publicado: (2020) -
HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F‐actin signalling pathway
por: Chen, Qian, et al.
Publicado: (2021) -
Targeting Unconventional Pathways in Pursuit of Novel Antifungals
por: Nguyen, Stephanie, et al.
Publicado: (2021)